Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lannett New York Listing Under Threat As FDA Says No On Advair

Flurry Of Announcements Also Sees Lannett Agree Sale Of Carmel Site

Executive Summary

A strained balance sheet and share price has led the New York Stock Exchange to write to Lannett about its future listing, adding to its woes as the FDA confirmed it was not currently in a position to approve its partnered generic Advair Diskus asset.

You may also be interested in...



Lannett: Pricing Pressure Has ‘Intensified Beyond Historical Norms’

Not many firms report a negative EBITDA when adjusted for costs, but this was the fate of Lannett during its financial Q2. Management addressed the challenges for Lannett’s base business and the ways in which the firm intends to turn the tide in the coming years.

Lannett Looks To Transform Company With Five Pipeline Assets

With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio. 

FDA Hands Lannett Goal Date On Generic Advair

Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel